Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression in Microbial Systems – To Facilitate Economical Scale-up in Production of Biologics
Oulu, Finland:– PARAS BIOPHARMA (BIOLOGICS CDMO) FINLAND, a leading biopharmaceutical technology development company in the Nordic region, maximises recombinant protein expression in Microbial Systems in its fully-equipped biologics production facility in Finland.
The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein – fully folded / biologically active in fermentation broth in scale-up studies which can be produced to commercial scale. This advanced Biomultifold system will be in place and available for future projects to facilitate and bring down costs. Previously, Paras Biopharma achieved 5-8 g / L in expression levels of a specific therapeutic protein.
Advanced Biomultifold Technology will further facilitate higher expression & production levels for Biologics in critical care / rare disease biologics (manufacturing), thus help to bring down the scale-up biologics promark.jackson@parasbiopharma.comduction costs / unit. The company is pleased to bring these developments in ongoing & upcoming projects on biologics and also to share this knowledge for client biologics CDMO work, as needed.
Full-service expertise for Scale-up Biologics Manufacturing at Paras Biopharma (Biologics CDMO) Finland, using its unique Biomultifold® Technology, can be found at https://www.parasbiopharma.com/technology/biomultifold-technology.php.
About Paras Biopharmaceuticals Finland Oy: Paras Biopharmaceuticals has a fully owned state-of-art 25,000ft² biologics production plant and is a revenue-generating and profit-making company. It has a proven track record of serving innovative big-pharma, medium-size and small-biotech start-up in USA & Europe for developing and producing small- and large-scale biologics production batches.
The company’s biologics production facility in located in Finland and is dedicated for the production of recombinant therapeutic products in microbial systems. The facility has classified cleanrooms covering 4,300 ft², and contains specialised features including media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.
Paras Biopharmaceuticals has a strong pipeline of Biologics & Biosimilars in Osteoporosis, Rheumatoid Arthritis, Onco-immunology and Urology. For more information, please see the Biosimilars development pipeline via www.parasbiologics.com or http://www.parasbiopharma.com/biosimilars/biosimilars.php
For further information, please contact:
Media Relations & Information
Dr. Mark Jackson Tel: +358 442709462 / Email: mark.jackson@parasbiopharma.com
